<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ScientificWorldJournal</journal-id><journal-id journal-id-type="iso-abbrev">ScientificWorldJournal</journal-id><journal-id journal-id-type="publisher-id">TSWJ</journal-id><journal-title-group><journal-title>The Scientific World Journal</journal-title></journal-title-group><issn pub-type="ppub">2356-6140</issn><issn pub-type="epub">1537-744X</issn><publisher><publisher-name>TheScientificWorldJOURNAL</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21403978</article-id><article-id pub-id-type="pmc">5720024</article-id><article-id pub-id-type="publisher-id">868459</article-id><article-id pub-id-type="doi">10.1100/tsw.2011.43</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Results of a Randomized, Open-Label, Clinical Trial Investigating the Effects of Supplementation with <italic>Heracleum persicum</italic> Extract as an Adjunctive Therapy for Dyslipidemia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Panahi</surname><given-names>Yunes</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pishgoo</surname><given-names>Bahram</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Beiraghdar</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Araghi</surname><given-names>Zahra Mohammadi</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sahebkar</surname><given-names>Amirhossein</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Abolhasani</surname><given-names>Ehsan</given-names></name><xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>
Chemical Injuries Research Center,
Baqiyatallah University of Medical Sciences,
Tehran,
Iran
</aff><aff id="I2">
<sup>2</sup>
Department of Cardiology,
Baqiyatallah University of Medical Sciences,
Tehran,
Iran
</aff><aff id="I3">
<sup>3</sup>
Nephrology and Urology Research Center,
Baqiyatallah University of Medical Sciences,
Tehran,
Iran
</aff><aff id="I4">
<sup>4</sup>
Pharmaceutical Sciences Branch,
Islamic Azad University,
Tehran,
Iran
</aff><aff id="I5">
<sup>5</sup>
Cardiovascular Research Center,
Avicenna Research Institute,
Mashhad University of Medical Sciences (MUMS),
Mashhad,
Iran
</aff><aff id="I6">
<sup>6</sup>
Biotechnology Research Center and School of Pharmacy,
Mashhad University of Medical Sciences (MUMS),
Mashhad,
Iran
</aff><aff id="I7">
<sup>7</sup>
Medicine Faculty,
Shaheed Beheshti University of Medical Sciences,
Tehran,
Iran
</aff><author-notes><corresp id="cor1">*Yunes Panahi: <email>yunespanahi@yahoo.com</email></corresp><fn fn-type="other"><p>Academic Editor: Ursula Wolf</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>7</day><month>3</month><year>2011</year></pub-date><volume>11</volume><fpage>592</fpage><lpage>601</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2010</year></date><date date-type="rev-recd"><day>25</day><month>12</month><year>2010</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Yunes Panahi et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The present study evaluated the potential benefit of supplementation with <italic>Heracleum persicum</italic> as an adjunctive therapy to atorvastatin in dyslipidemic subjects. In a randomized, open-label, clinical trial, 100 dyslipidemic subjects were randomly assigned to: (1) <italic>H. persicum</italic> group (<italic>n</italic> = 50, completers = 18), receiving <italic>H. persicum</italic> extract (500&#x02009;mg/day) + atorvastatin (10&#x02009;mg/day) for 8 weeks, or (2) atorvastatin group (<italic>n</italic> =50, completers= 34), receiving only atorvastatin (20&#x02009;mg/day) for 8 weeks. Weight, body mass index (BMI), lipid profile, and biomarkers of hepatic and renal injury were determined at baseline and at the end of the trial. There were significant reductions in serum total cholesterol and LDL-C in both the <italic>H. persicum</italic> (<italic>p</italic> = 0.001) and atorvastatin (<italic>p</italic> &#x0003c; 0.05) groups. Serum HDL-C was elevated in the atorvastatin group (<italic>p</italic> &#x0003c; 0.05), while no significant change was observed in the <italic>H. persicum</italic> group (<italic>p</italic> &#x0003e; 0.05). Serum triglyceride levels remained statistically unchanged by the end of the trial in both groups (<italic>p</italic> &#x0003e; 0.05). Serum alanine (<italic>p</italic> = 0.049) and aspartate aminotransferase (<italic>p</italic> = 0.013) levels rose in the atorvastatin, but not the <italic>H. persicum</italic> (<italic>p</italic> &#x0003e; 0.05) group. In comparison with baseline values, no significant change was observed in weight and BMI, as well as serum levels of creatinine, blood urea nitrogen, and fasting blood sugar in either of the groups (<italic>p</italic> &#x0003e; 0.05). Apart from HDL-C, the effects of atorvastatin (20&#x02009;mg/day) on other lipid profile parameters do not appear to be significantly superior to those achieved by combination therapy with <italic>H. persicum</italic> + atorvastatin (10&#x02009;mg/day).</p></abstract><kwd-group><kwd>Heracleum persicum</kwd><kwd>atorvastatin</kwd><kwd>dyslipidemia</kwd><kwd>cholesterol</kwd><kwd>triglycerides</kwd></kwd-group></article-meta></front></article>